Grufity logoGrufity logo

SKIN

10.87USD+0.12(+1.12%)Market Closed

SKINOVATION PHARMACEUTICAL INC

Market Summary

USD10.87+0.12Market Closed
1.12%

SKIN Stock Price

RSI Chart

Valuation

Market Cap

8.4M

Price/Earnings

-0.04

Price/Sales

0.03

Price/Cashflow

-1.2K

MarketCap/EBT

-0.02

Price/Sales

Profitability

Operating Margin

70.16%

EBT Margin

-117.60%

Return on Equity

-68.03%

Return on Assets

-19.39%

Fundamentals

Revenue

Revenue (TTM)

288.0M

Revenue Y/Y

58.63%

Revenue Q/Q

-3.18%

Earnings

Earnings (TTM)

-232.5M

Earnings Y/Y

99.99%

Earnings Q/Q

25.51%

Price Action

52 Week Range

8.2725.85
(Low)(High)

Last 7 days

7.7%

Last 30 days

-3.0%

Last 90 days

-5.3%

Trailing 12 Months

-55.8%

Financial Health

Current Ratio

2e-4

Investor Care

Diluted EPS (TTM)

-1.34

Peers (Alternatives to SKINOVATION PHARMACEUTICAL)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
2.4T
394.3B
-1.39% -9.47%
23.66
5.99
7.79% 5.41%
1.8T
203.1B
11.94% -22.12%
25.2
8.66
15.22% 2.81%
1.3T
282.1B
11.91% -28.48%
18.7
4.44
17.94% -5.14%
952.9B
502.2B
-1.33% -44.54%
84.16
1.9
9.66% -56.89%
MID-CAP
2.5B
8.6B
-0.75% -38.10%
-5.69
0.31
76.30% -20.89%
SMALL-CAP
1.9B
628.4M
9.16% -55.02%
-4.08
3.1
64.35% -18.14%
1.9B
1.6B
3.00% 30.03%
12.45
1.23
81.91% 208.48%
1.5B
-
12.61% -60.46%
-0.54
1.95
-4.11% -144.36%
1.4B
40.0M
-23.53% -72.63%
-1.84
34.64
34.91% -55.12%
1.0B
247.8M
8.68% -10.08%
-17.78
4.46
23.41% -194.70%
1.0B
412.4M
12.12% -23.98%
-153.63
2.47
51.09% -102.33%
988.1M
439.7M
-6.53% -78.39%
-2.97
2.13
-5.64% -199.38%
861.5M
1.2B
-1.81% -46.23%
2.31
0.73
7.66% 583.60%
551.2M
2.2M
-9.43% -70.91%
-1.55
343.43
-72.60% -50.32%

Financials for SKINOVATION PHARMACEUTICAL

Income Statement (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q12021Q42021Q32021Q22021Q1
Revenue10.7%287,959260,086220,077186,490134,098
Gross Profit11.1%202,024181,827148,103122,98580,010
Operating Expenses-47.1%115,512218,46634,5771,218
  S&GA Expenses-318659.4%-44,056.761413,137-6,772.67
  R&D Expenses9.5%8,9738,1957,1805,8773,486
Earnings Before Taxes10.3%-338,648.00-377,350.00-371,643.00-158,176.00-30,377.00
Net Income0.9%-371,844.44-375,108.00-437,200.30-224,269.30
Balance Sheet
(In Thousands)
Description(%) Q/Q2022Q12021Q42021Q32021Q22021Q1
Assets-1.6%1,199,1781,218,806997,875730,704463,533
  Current Assets-49.5%112*222*797,80523,349
    Cash Equivalents-49.5%112*222*718,622214,115
  Inventory33.4%47,03335,26128,10523,762-
  Net PPE19.4%12,07010,113---
  Goodwill0.1%123,774123,694122,865103,10098,535
Liabilities-50.0%380,241760,0851,139,930604,16868,407
  Current Liabilities2.7%38837849,468364813
Shareholder's Equity13.0%341,708302,29716,070--
  Retained Earnings99.9%-413.89-418,712.00-401,401.00-388.46-68,016.29
  Additional Paid-In Capital0%2525260,908253,104
Shares Outstanding-100.0%-150,598133,490--
Float------
* denotes actual numbers (not divided by Thousands)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations99.5%-6.77-1,272.94-6.83-32,733.48-1,099.22
  Share Based Compensation56.5%19,43312,4188,6613,655
Cashflow From Investing0%-37,731.00-37,731.00-37,731.00-38,934.67-1,696.00
Cashflow From Financing100.1%5-4,368.5041,235,159464,363
  Buy Backs-0
* denotes actual numbers (not divided by Thousands)

Risks

What is the probability of a big loss on SKIN?

63.4%


Probability that SKINOVATION PHARMACEUTICAL stock will be more than 20% underwater in next one year

56.1%


Probability that SKINOVATION PHARMACEUTICAL stock will be more than 30% underwater in next one year.

56.1%


Probability that SKINOVATION PHARMACEUTICAL stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SKIN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if SKINOVATION PHARMACEUTICAL was unfortunately bought at previous high price.

Returns

Cumulative Returns on SKIN

Which funds bought or sold SKIN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
Parallax Volatility Advisers, L.P.
REDUCED
-56.55
-34,000
23,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-153,000
1,381,000
-%
2022-11-17
M&T Bank Corp
NEW
-
452,000
452,000
-%
2022-11-17
CENTRAL TRUST Co
SOLD OFF
-100
-
-
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-1,000
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
Balyasny Asset Management LLC
ADDED
86.08
1,129,000
2,727,000
0.01%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
-18,000
200,000
-%
2022-11-15
ALLIANCEBERNSTEIN L.P.
REDUCED
-12.41
-909,000
3,708,000
-%
2022-11-15
JANE STREET GROUP, LLC
ADDED
311.1
2,218,000
3,019,000
-%

1–10 of 34

Latest Funds Activity

Are funds buying SKIN calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own SKIN

SKINOVATION PHARMACEUTICAL News

SKIN Fair Value

Recent SEC filings of SKINOVATION PHARMACEUTICAL

View All Filings
Date Filed Form Type Document
Nov 03, 2022
10-Q
Quarterly Report
Andrew Stanleick
700
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.

SKIN Income Statement

2022-09-30
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
REVENUES
OPERATING EXPENSES    
General and administrative2,7602,80011,25011,000
TOTAL EXPENSES2,7602,80011,25011,000
Loss from operations(2,760)(2,800)(11,250)(11,000)
OTHER INCOME (EXPENSE)    
Interest expense(4,969)(4,680)(14,704)(13,940)
Total other income (expense)(4,969)(4,680)(14,704)(13,940)
LOSS BEFORE INCOME TAXES(7,729)(7,480)(25,954)(24,940)
INCOME TAX EXPENSE  
NET LOSS$ (7,729)$ (7,480)$ (25,954)$ (24,940)
Basic and diluted net loss per share$ (0.01)$ (0.01)$ (0.04)$ (0.04)
Basic and diluted weighted average shares outstanding708,000708,000708,000708,000

SKIN Balance Sheet

2022-09-30
Condensed Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current Assets  
Cash$ 1,472$ 222
Total Current Assets1,472222
Total Assets1,472222
Current Liabilities  
Accounts payable10,5007,000
Notes payable249,021240,021
Accrued interest145,497130,793
Total Current Liabilities405,018377,814
Total Liabilities405,018377,814
Stockholders' Deficit  
Preferred stock, $.001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $.001 par value; 50,000,000 shares authorized; 708,000 shares issued and outstanding708708
Additional paid-in capital25,14825,148
Accumulated deficit(429,402)(403,448)
Total Stockholders' Deficit(403,546)(377,592)
Total Liabilities and Stockholders' Deficit$ 1,472$ 222